Morgan Stanley Myriad Genetics Inc Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Myriad Genetics Inc stock. As of the latest transaction made, Morgan Stanley holds 4,554,080 shares of MYGN stock, worth $27.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,554,080

Previous 1,614,582 182.06%

Holding current value

$27.5 Million

Previous $14.3 Million 68.86%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$3.84 - $8.84 $11.3 Million - $26 Million	2,939,498 Added 182.06%	4,554,080 $24.2 Million
Q1 2025 May 15, 2025	BUY	$8.87 - $14.98 $2.92 Million - $4.94 Million	329,465 Added 25.64%	1,614,582 $14.3 Million
Q4 2024 Feb 14, 2025	BUY	$13.17 - $27.03 $5.32 Million - $10.9 Million	404,130 Added 45.87%	1,285,117 $17.6 Million
Q3 2024 May 14, 2025	SELL	$23.97 - $28.6 $11.8 Million - $14.1 Million	-491,650 Reduced 35.82%	880,987 $24.1 Million
Q3 2024 Nov 14, 2024	SELL	$23.97 - $28.6 $11.8 Million - $14.1 Million	-491,650 Reduced 35.82%	880,987 $24.1 Million
Q2 2024 May 14, 2025	BUY	$17.98 - $25.47 $1.57 Million - $2.23 Million	87,520 Added 6.81%	1,372,637 $33.6 Million
Q2 2024 Oct 17, 2024	SELL	$17.98 - $25.47 $5.38 Million - $7.62 Million	-299,116 Reduced 17.89%	1,372,637 $33.6 Million
Q2 2024 Aug 14, 2024	SELL	$17.98 - $25.47 $5.38 Million - $7.62 Million	-299,116 Reduced 17.89%	1,372,637 $33.6 Million
Q1 2024 Oct 17, 2024	BUY	$17.59 - $23.59 $5.26 Million - $7.06 Million	299,116 Added 21.79%	1,671,753 $35.6 Million
Q1 2024 Aug 16, 2024	BUY	$17.59 - $23.59 $14.7 Million - $19.7 Million	835,846 Added 99.99%	1,671,753 $35.6 Million
Q1 2024 May 15, 2024	BUY	$17.59 - $23.59 $14.7 Million - $19.7 Million	835,846 Added 99.99%	1,671,753 $35.6 Million
Q4 2023 Aug 16, 2024	SELL	$13.91 - $21.32 $7.47 Million - $11.4 Million	-536,730 Reduced 39.1%	835,907 $16 Million
Q4 2023 Feb 13, 2024	BUY	$13.91 - $21.32 $3.91 Million - $6 Million	281,255 Added 50.71%	835,907 $16 Million
Q3 2023 Nov 15, 2023	SELL	$15.99 - $23.22 $1.47 Million - $2.14 Million	-91,974 Reduced 14.22%	554,652 $8.9 Million
Q2 2023 Aug 14, 2023	BUY	$17.56 - $23.76 $372,693 - $504,282	21,224 Added 3.39%	646,626 $15 Million
Q1 2023 May 15, 2023	SELL	$15.26 - $23.75 $4.14 Million - $6.45 Million	-271,479 Reduced 30.27%	625,402 $14.5 Million
Q4 2022 Feb 14, 2023	BUY	$14.51 - $20.99 $3.08 Million - $4.45 Million	212,232 Added 31.0%	896,881 $13 Million
Q3 2022 Nov 14, 2022	SELL	$18.21 - $27.88 $605,646 - $927,260	-33,259 Reduced 4.63%	684,649 $13.1 Million
Q2 2022 Oct 27, 2022	BUY	$16.45 - $25.88 $2.3 Million - $3.62 Million	140,060 Added 24.24%	717,908 $13 Million
Q2 2022 Aug 15, 2022	BUY	$16.45 - $25.88 $2.3 Million - $3.62 Million	140,060 Added 24.24%	717,908 $13 Million
Q1 2022 Oct 27, 2022	SELL	$22.67 - $28.01 $3.18 Million - $3.92 Million	-140,060 Reduced 19.51%	577,848 $14.6 Million
Q1 2022 May 13, 2022	BUY	$22.67 - $28.01 $2.73 Million - $3.38 Million	120,611 Added 26.38%	577,848 $14.6 Million
Q4 2021 Feb 14, 2022	SELL	$24.13 - $32.63 $9.76 Million - $13.2 Million	-404,501 Reduced 46.94%	457,237 $12.6 Million
Q3 2021 Nov 15, 2021	BUY	$29.97 - $36.66 $25.8 Million - $31.6 Million	861,738 New	861,738 $27.8 Million

Others Institutions Holding MYGN

# of Institutions

232

Shares Held

94.1M

Call Options Held

450K

Put Options Held

14.2K

View Full List

About MYRIAD GENETICS INC

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $486M
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

More about MYGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account